The Swedish company has signed an exclusive agreement with Mundipharma to commercialize Emtrix in the Middle East and Africa, starting in 2019.
Emtrix is Moberg’s lead fungal nail product. The company will exclusively supply the product, and Mundipharma will be responsible for local registration and commercialization in the Middle East and Africa, focusing initially on three markets in the region.
“We look forward to developing our relationship with Mundipharma and making Emtrix available in new regions as we expand our footprint in growing markets,” says Peter Wolpert, Moberg Pharma’s CEO.
“This newly signed agreement with Moberg Pharma will give onychomycosis patients in MEA region access to one of the leading treatments for this common and uncomfortable nail fungal condition”, said Dr. Ashraf Allam, Vice President of Mundipharma META.